

Current Report No 28/2022

Completion of the Company's financing phase and conclusion of loan agreements

The Management Board of Genomtec S.A. based in Wrocław ("Issuer", "Company"; "Borrower") announces that on 13 December 2022 it finalised the financing stage of the Company by completing the process of concluding loan agreements with the right to acquire the Company's shares with natural persons and legal entities ("Lenders"), including today (13 December 2022) the Issuer concluded with a legal entity based in Poland two loan agreements with the right to acquire the Company's shares for a total amount of PLN 2.9 million. The remaining agreements were concluded for smaller amounts not exceeding PLN 400,000.

Under the aforementioned agreements, the Company raised a total of PLN 4.4 million to improve its cash position and implement the Company's future strategy.

Loans can be repaid as follows:

- cash repayment due by 31 December 2023, with the repayment term reserved in favour of the Borrower, i.e. the Borrower has the right to repay part or all of the Loans early
- subscription of the Borrower's new issue shares by the Lenders (the "Share Subscription Right"). Repayment of the Loan by way of the Share Subscription Right is a right of the Borrower, i.e. the Company has the right to repay the Loan by way of the Share Subscription Right and, in the event that the Borrower makes a declaration to exercise this right, the Borrower and the Lenders undertake to carry out the repayment by way of the Share Subscription Right. Under the Share Subscription Right, the Borrowers shall be entitled to subscribe for such number of shares in the Company as shall be calculated as the quotient of: (a) the amount of the Loan paid and not repaid, together with the interest due, and (b) the issue price of PLN 5.00 (five zlotys), which has been determined as the average price of the Issuer's shares on the NewConnect market weighted by trading volume for the last 3 months calculated as at the date of the Loan Agreement, less a discount of not more than 10%.

The provision of funds to support the implementation of the Company's announced strategy is a material event for the Company's business and, in the opinion of the Board of Directors, meets the criteria for confidential information within the meaning of Article 17(1) MAR.

